Construct: ORF ccsbBroad304_11604
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF013395.1_s304c1, BRDN0000398718
- Derived from:
- ccsbBroadEn_11604
- DNA Barcode:
- None
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- RABL2B (11158)
Vector Information:
- Vector Backbone:
- pLX_304
- Pol II Cassette 1:
- PGK-BlastR
- Pol II Cassette 2:
- CMV-ccsbBroad304_11604
- Selection Marker:
- BlastR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
---|---|---|---|---|---|---|---|---|
1 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028559.2 | 85.3% | 85.3% | 298_348del |
2 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003234.1 | 59.1% | 45% | (many diffs) |
3 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354424.2 | 52.6% | 43.6% | (many diffs) |
4 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306161.2 | 52.1% | 43.3% | (many diffs) |
5 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354421.2 | 52.1% | 43.3% | (many diffs) |
6 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354423.2 | 52.1% | 43.3% | (many diffs) |
7 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003226.1 | 52.1% | 43.3% | (many diffs) |
8 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354418.2 | 51.5% | 40.9% | (many diffs) |
9 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354419.2 | 51.5% | 40.9% | (many diffs) |
10 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003223.1 | 51.5% | 40.9% | (many diffs) |
11 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354417.2 | 43.7% | 43.7% | (many diffs) |
12 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130922.3 | 43.4% | 43.4% | 298_684del |
13 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350005.2 | 43.4% | 43.4% | 298_684del |
14 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350006.2 | 43.4% | 43.4% | 298_684del |
15 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350007.2 | 43.4% | 43.4% | 298_684del |
16 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_007081.4 | 43.4% | 43.4% | 298_684del |
17 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028556.1 | 43.4% | 43.4% | 298_684del |
18 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001003789.3 | 43.2% | 43.2% | 298_687del |
19 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130919.3 | 43.2% | 43.2% | 298_687del |
20 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130920.3 | 43.2% | 43.2% | 298_687del |
21 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130921.3 | 43.2% | 43.2% | 298_687del |
22 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350003.2 | 43.2% | 43.2% | 298_687del |
23 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350004.2 | 43.2% | 43.2% | 298_687del |
24 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028552.1 | 43.2% | 43.2% | 298_687del |
25 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028555.1 | 43.2% | 43.2% | 298_687del |
26 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_024452147.1 | 43.2% | 43.2% | 298_687del |
27 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354416.2 | 42.9% | 42.9% | (many diffs) |
28 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_007082.5 | 42.9% | 42.9% | (many diffs) |
29 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_013412.4 | 42.9% | 42.9% | (many diffs) |
30 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003220.1 | 42.9% | 42.9% | (many diffs) |
31 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003222.1 | 42.9% | 42.9% | (many diffs) |
32 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306158.2 | 42.7% | 42.7% | (many diffs) |
33 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306159.2 | 42.7% | 42.7% | (many diffs) |
34 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354412.2 | 42.7% | 42.7% | (many diffs) |
35 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354413.2 | 42.7% | 42.7% | (many diffs) |
36 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354414.2 | 42.7% | 42.7% | (many diffs) |
37 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003213.1 | 42.7% | 42.7% | (many diffs) |
38 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003214.1 | 42.7% | 42.7% | (many diffs) |
39 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003215.1 | 42.7% | 42.7% | (many diffs) |
40 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003216.1 | 42.7% | 42.7% | (many diffs) |
41 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452575.1 | 42.7% | 42.7% | (many diffs) |
42 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028551.1 | 42.3% | 42.3% | 298_702del |
43 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350016.2 | 42.1% | 42.1% | 298_705del |
44 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350017.2 | 42.1% | 42.1% | 298_705del |
45 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003212.1 | 41.8% | 41.8% | (many diffs) |
46 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003210.1 | 41.7% | 41.7% | (many diffs) |
47 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003211.1 | 41.7% | 41.7% | (many diffs) |
48 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130923.3 | 41.5% | 41.5% | 298_714del |
49 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350013.2 | 41.5% | 41.5% | 298_714del |
50 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350014.2 | 41.5% | 41.5% | 298_714del |
51 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350015.2 | 41.5% | 41.5% | 298_714del |
52 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028547.1 | 41.5% | 41.5% | 298_714del |
53 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350008.2 | 41.4% | 41.4% | 298_717del |
54 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350009.2 | 41.4% | 41.4% | 298_717del |
55 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350010.2 | 41.4% | 41.4% | 298_717del |
56 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350011.2 | 41.4% | 41.4% | 298_717del |
57 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350012.2 | 41.4% | 41.4% | 298_717del |
58 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028543.1 | 41.4% | 41.4% | 298_717del |
59 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028544.1 | 41.4% | 41.4% | 298_717del |
60 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028546.1 | 41.4% | 41.4% | 298_717del |
61 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306160.3 | 41.1% | 41.1% | (many diffs) |
62 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354410.2 | 41.1% | 41.1% | (many diffs) |
63 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452573.1 | 41.1% | 41.1% | (many diffs) |
64 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354405.2 | 41% | 41% | (many diffs) |
65 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354406.2 | 41% | 41% | (many diffs) |
66 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354407.2 | 41% | 41% | (many diffs) |
67 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354408.2 | 41% | 41% | (many diffs) |
68 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354409.2 | 41% | 41% | (many diffs) |
69 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712208.3 | 41% | 41% | (many diffs) |
70 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712209.3 | 41% | 41% | (many diffs) |
71 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_011510509.2 | 41% | 41% | (many diffs) |
72 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003203.1 | 41% | 41% | (many diffs) |
73 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003204.1 | 41% | 41% | (many diffs) |
74 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003205.1 | 41% | 41% | (many diffs) |
75 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003207.1 | 41% | 41% | (many diffs) |
76 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148879.2 | 14.5% | (many diffs) | |
77 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148882.2 | 14.4% | (many diffs) | |
78 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148881.2 | 14.4% | (many diffs) | |
79 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148880.2 | 13.3% | (many diffs) | |
80 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XR_002959036.1 | 11.7% | (many diffs) | |
81 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521326.3 | 38.4% | 39.1% | (many diffs) |
82 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | NM_026817.3 | 38.2% | 39% | (many diffs) |
83 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521327.3 | 25.1% | 27.3% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 363
- ORF length:
- 297
- Sequence:
-
1 ggtctatata agcagagctc tctggctaac tgtcgggatc aacaagtttg tacaaaaaag 61 ttggcatggc agaagacaaa accaaaccga gtgagttgga ccaagggaag tatgatgctg 121 atgacaacgt gaagatcatc tgcctgggag acagcgcagt gggcaaatcc aaactcatgg 181 agagatttct catggatggc tttcagccac agcagctgtc cacgtacgcc ctgaccctgt 241 acaagcacac agccacggta gatggaagga ccatccttgt ggacttttgg gacacggcag 301 gccaggagcg gttccagagc atgcatgcct cctactacca caaggcccac gcctgcatca 361 tgtgcccaac tttcttgtac aaagtggttg gtaagcctat ccctaaccct ctcctcggtc 421 tcgattctac gtagtaatga gctagcgcta accggtggcg cgttaagtcg acaatcaacc 481 tctggatta